Hematology

Latest News

There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com
Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

July 11th 2025

There are molecular testing gaps in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) treatment, highlighting the need for improved testing and targeted therapy integration.

The findings have potential implications for treatment selection in CLL/SLL, particularly in patients at elevated risk for infectious complications. | Image credit: Eleni - stock.adobe.com
Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL

July 7th 2025

Artwork of community health care with a giant stethoscope and medicine bag | Image credit: TarikVision - stock.adobe.com.
Academic-Community Partnerships Bringing Cancer Care to Patients

July 5th 2025

Clinical trial graphic | Image credit: photon_photo - stock.adobe.com
Comparative Analysis Suggests Zanubrutinib as Most Effective cBTKi in R/R CLL

July 5th 2025

White blood cells | Image credit: Sebastian Kaulitzki - stock.adobe.com
Basophil, Eosinophil Counts Could Be Prognostic Indicators in ET, PV

July 2nd 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Clinical Impact of the RESONATE-2 Trial in CLL
July 11th 2018

Clinical Impact of the RESONATE-2 Trial in CLL

CLL: Managed Care Outlook on Clinical Trial Data
July 11th 2018

CLL: Managed Care Outlook on Clinical Trial Data

Coverage and Clinical Support in CLL Treatment
July 11th 2018

Coverage and Clinical Support in CLL Treatment

Diagnostic Factors and Treatment Changes in CLL
July 11th 2018

Diagnostic Factors and Treatment Changes in CLL

CLL: Addressing Treatment Paradigms and Unmet Needs
July 11th 2018

CLL: Addressing Treatment Paradigms and Unmet Needs

CLL: Unmet Needs and Future Outlook
July 11th 2018

CLL: Unmet Needs and Future Outlook

Rationale for Novel Combinations in CLL
July 11th 2018

Rationale for Novel Combinations in CLL

CLL: Data Impact and Sequencing Approach
July 11th 2018

CLL: Data Impact and Sequencing Approach

Clinical Significance of Upfront Ibrutinib in CLL
July 11th 2018

Clinical Significance of Upfront Ibrutinib in CLL

CLL: When to Initiate Frontline Therapy
July 11th 2018

CLL: When to Initiate Frontline Therapy

Identifying Mutational Status in CLL
July 11th 2018

Identifying Mutational Status in CLL

Diagnosing Chronic Lymphocytic Leukemia
July 11th 2018

Diagnosing Chronic Lymphocytic Leukemia

Site Logo
July 11th 2018

Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia

Kelly Fust, MS Anju Parthan, PhD Xiaoyan Li, PhD Anjali Sharma, MD Xinke Zhang, MS Marco Campioni, PhD Junji Lin, PhD, MS Xuena Wang, PhD Richard Zur, PhD Karynsa Cetin, MPH Melissa Eisen, MD David Chandler, PhD
This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.
Patients With Newly Diagnosed MM Taking Twice-Weekly Ixazomib Achieve High ORR
July 10th 2018

Patients With Newly Diagnosed MM Taking Twice-Weekly Ixazomib Achieve High ORR

Laura Joszt, MA
Ixazomib taken twice weekly with lenalidomide and dexamethasone resulted in high overall response rate (ORR) and a durable response among patients with newly diagnosed multiple myeloma (MM).
Research Highlights Long-Term Survival and Health-Related QoL in Patients With Newly Diagnosed MM
July 6th 2018

Research Highlights Long-Term Survival and Health-Related QoL in Patients With Newly Diagnosed MM

Laura Joszt, MA
Research presented at the 2018 American Society of Clinical Oncology Annual Meeting identified predictors of long-term survival and health-related quality of life (QoL) in patients with newly diagnosed multiple myeloma (MM).
Review Finds Time to Diagnosis for Multiple Myeloma Can Be Significantly Reduced
July 5th 2018

Review Finds Time to Diagnosis for Multiple Myeloma Can Be Significantly Reduced

Laura Joszt, MA
A review of studies found that the time from symptom onset to confirmation of diagnosis of multiple myeloma can be significantly reduced. Currently, many patients experience a more than 3-month delay until their diagnosis is confirmed.
Glasdegib Receives Priority Review Based on Results It Nearly Doubles OS in AML
June 30th 2018

Glasdegib Receives Priority Review Based on Results It Nearly Doubles OS in AML

Laura Joszt, MA
Based on trial results that showed glasdegib, an investigational oral smoothened inhibitor, nearly doubled overall survival (OS) in patients with previously untreated acute myeloid leukemia (AML), the FDA has granted the Pfizer drug a Priority Review.
Mutation in T-Cell ALL Enables Cancer Cells to Survive Chemotherapy
June 27th 2018

Mutation in T-Cell ALL Enables Cancer Cells to Survive Chemotherapy

Laura Joszt, MA
Cancer cells can take advantage of the BCL-2 protein to survive chemotherapy, but a drug that suppresses BCL-2 may have promise in patients with leukemia who produce too much of the protein.
Patients With Myelofibrosis Treated With JAK1/2 Inhibitors at Increased Risk of Lymphomas
June 22nd 2018

Patients With Myelofibrosis Treated With JAK1/2 Inhibitors at Increased Risk of Lymphomas

Laura Joszt, MA
Patients with myelofibrosis who were treated with Janus-kinase (JAK) 1/2 inhibitors have an increased risk for developing B-cell lymphoma. However, researchers believe there is a pre-existing B-cell clone that patients can be tested for before treatment.
Quizartinib Prolongs Overall Survival in Deadly Form of AML Compared With Chemotherapy
June 19th 2018

Quizartinib Prolongs Overall Survival in Deadly Form of AML Compared With Chemotherapy

Laura Joszt, MA
An investigational drug has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia (AML).
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16th 2018

Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies

Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, outlines novel therapies being used in the treatment of hematologic malignancies and identified biomarkers for deciding on a treatment approach.
Gene Editing Could Reduce Toxicity of CAR T Treatment in AML
June 15th 2018

Gene Editing Could Reduce Toxicity of CAR T Treatment in AML

Laura Joszt, MA
A new approach using gene editing technology could allow chimeric antigen receptor (CAR) T cells to target CD33 in patients with acute myeloid leukemia (AML) but prevent the cells from attacking healthy stem cells, too.
Translocated Bacteria Can Lead to a Precursor Condition of Leukemia
June 12th 2018

Translocated Bacteria Can Lead to a Precursor Condition of Leukemia

Laura Joszt, MA
A stem cell mutation that leads to bacterial translocation may help identify patients at risk of developing leukemia.
Once-Weekly Carfilzomib Superior to Twice-Weekly Regimen in Relapsed/Refractory Multiple Myeloma
June 6th 2018

Once-Weekly Carfilzomib Superior to Twice-Weekly Regimen in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA
The interim analysis of the phase 3 A.R.R.O.W. trial found that once-weekly carfilzomib at 70 mg/m2 had superior progression-free survival and overall response rates compared with twice-weekly carfilzomib at 27 mg/m2.
Experimental Drug Creates Durable Remission in Patients With AML With IDH1 Mutations
June 4th 2018

Experimental Drug Creates Durable Remission in Patients With AML With IDH1 Mutations

Laura Joszt, MA
An experimental drug for patients with acute myeloid leukemia (AML) with mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) was found to be safe with durable remissions.
Analyzing Worries in Leukemia and Economic Burden in Lymphoma
June 2nd 2018

Analyzing Worries in Leukemia and Economic Burden in Lymphoma

Laura Joszt, MA
Two abstracts presented at the International Society of Pharmacoeconomic and Outcomes Research Annual International Meeting highlighted patient experiences in blood cancers. One highlighted the worries of patients with acute myeloid leukemia, and the other analyzed economic burdens and resource utilization for patients with non-Hodgkin lymphoma.
Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma
May 31st 2018

Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma

Laura Joszt, MA
Two study abstracts presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting look at the cost burden of diffuse large B-cell lymphoma (DLBCL). One analyzed the lifetime cost of relapsed/refractory DLBCL, including third-line and subsequent treatments, and the other examined how being diagnosed with DBLCL can increase the cost burden of chronic conditions among Medicare beneficiaries.
Analysis Outlines Global Burden of Multiple Myeloma, Access to Effective Treatments
May 26th 2018

Analysis Outlines Global Burden of Multiple Myeloma, Access to Effective Treatments

Laura Joszt, MA
A new study analyzed the burden of multiple myeloma around the world, as well as access to effective treatments. From 1990 to 2016, incident cases and deaths from the disease have grown substantially.
Patients With ALL Taking Inotuzumab Ozogamicin Report Better Quality of Life Compared With Standard Therapy
May 24th 2018

Patients With ALL Taking Inotuzumab Ozogamicin Report Better Quality of Life Compared With Standard Therapy

Laura Joszt, MA
Analysis of patient-reported outcomes found patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were treated with inotuzumab ozogamicin reported better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.
Site Logo
May 18th 2018

Study Reports Highest Survival Rates for Children, Young Adults With Certain T-Cell Leukemias

Laura Joszt, MA
A phase III randomized trial, with results being presented in June at the American Society of Clinical Oncology Annual Meeting, found the addition of nelarabine to standard chemotherapy regimen in patients with T-cell malignancies can improve disease-free survival rates.
<1
...
171819202122232425
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo